Cardiovascular effects of overt and subclinical hyperthyroidism: focus on differentiated thyroid cancer

Thera P Links*, Trynke van der Boom, Wouter T Zandee, Joop D Lefrandt

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    6 Citations (Scopus)
    70 Downloads (Pure)


    Thyroid hormone stimulates cardiac inotropy and chronotropy via direct genomic and non-genomic mechanisms. Hyperthyroidism magnifies these effects, resulting in an increase in heart rate, ejection fraction and blood volume. Hyperthyroidism also affects thrombogenesis and this may be linked to a probable tendency towards thrombosis in patients with hyperthyroidism. Patients with hyperthyroidism are therefore at higher risk for atrial fibrillation, heart failure and cardiovascular mortality. Similarly, TSH suppressive therapy for differentiated thyroid cancer is associated with increased cardiovascular risk. In this review, we present the latest insights on the cardiac effects of thyroid suppression therapy for the treatment of thyroid cancer. Finally, we will show new clinical data on how to implement this knowledge into the clinical practice of preventive medicine.

    Original languageEnglish
    Article numberEC-20-0539
    Pages (from-to)R43-R51
    Number of pages9
    JournalEndocrine Connections
    Issue number1
    Early online date1-Dec-2020
    Publication statusPublished - Jan-2021

    Cite this